TMIGD2 expression has been found to be significantly upregulated in glioma patients, correlating with better overall survival and increased immune cell infiltration, and is negatively associated with pathways such as angiogenesis and hypoxia, suggesting its role in inhibiting tumor progression (Boulhen et al. 2023). Here, TMIGD2 is linked to neoplasm.